Go Pro
→ Jeff Brown and Marc Chaikin's latest AI prediction explained (From Brownstone Research) (Ad)tc pixel Free PRQR Stock Alerts

ProQR Therapeutics (PRQR) Financials

ProQR Therapeutics logo
$1.70 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.70 +0.01 (+0.29%)
As of 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for ProQR Therapeutics

Annual Income Statements for ProQR Therapeutics

This table shows ProQR Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -87 -174 -52 -42 -63 -57 -68 -68 -63 -57 -100
Consolidated Net Income / (Loss)		 -23 -174 -52 -42 -64 -57 -69 -69 -31 -29 -50
Net Income / (Loss) Continuing Operations		 -87 -174 -52 -42 -64 -57 -69 -70 -34 -29 -50
Total Pre-Tax Income 		-23 -43 -52 -42 -64 -57 -69 -69 -31 -29 -49
Total Operating Income		 -97 -176 -49 -42 -64 -52 -65 -70 -35 -32 -51
Total Gross Profit		 -64 -130 0.00 0.00 0.00 0.00 0.00 3.84 7.21 20 19
Total Revenue		 -30 -87 0.00 0.00 0.00 0.00 0.00 3.84 7.21 20 19
Operating Revenue		 -30 -87 - - - - - 3.84 7.21 20 19
Total Cost of Revenue		 34 44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 34 46 49 42 64 52 66 74 46 52 70
Selling, General & Admin Expense		 7.59 10 13 14 14 17 20 20 18 14 18
Research & Development Expense		 26 35 37 34 52 47 48 54 28 38 52
Total Other Income / (Expense), net		 10 2.54 -3.81 -0.91 0.45 -4.54 -2.14 -0.28 4.59 2.91 1.75
Interest Expense		 - - - - 1.22 4.92 3.85 5.48 1.61 1.12 1.51
Interest & Investment Income		 6.85 - - - 1.67 0.38 1.72 5.20 2.87 3.37 2.74
Other Income / (Expense), net		 3.59 2.54 -3.81 -0.91 - - - 0.00 3.33 0.66 0.52
Income Tax Expense		 0.00 0.00 0.00 0.00 0.15 0.15 0.13 0.10 -0.09 -0.20 0.02
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.00 0.00 - - - - - -0.24 -0.42 0.00 0.00
Basic Earnings per Share		 ($0.99) ($1.85) ($1.72) ($1.08) ($1.38) ($0.93) ($0.95) ($0.96) ($0.39) ($0.33) ($0.47)
Weighted Average Basic Shares Outstanding		 25.90M 25.85M 25.37M 34.05M 41.04M 50.06M 64.18M 71.64M 81.01M 86.09M 105.33M
Diluted Earnings per Share		 ($0.99) ($1.85) ($1.72) ($1.08) - - - ($0.96) ($0.39) ($0.33) ($0.47)
Weighted Average Diluted Shares Outstanding		 25.90M 25.85M 25.37M 34.05M 41.04M 50.06M 64.18M 71.64M 81.01M 86.09M 105.33M
Weighted Average Basic & Diluted Shares Outstanding		 25.90M 25.85M 25.37M 34.05M 41.04M 50.06M 64.18M 71.64M 81.01M 86.09M 105.36M

Quarterly Income Statements for ProQR Therapeutics

No quarterly income statements for ProQR Therapeutics are available.

Annual Cash Flow Statements for ProQR Therapeutics

This table details how cash moves in and out of ProQR Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -27 -41 -10 66 6.34 -41 126 -107 27 31 -67
Net Cash From Operating Activities		 -27 -38 -42 -33 -49 -57 4.04 -73 30 -38 -66
Net Cash From Continuing Operating Activities		 -27 -38 -42 -33 -49 -58 4.04 -67 30 -24 -66
Net Income / (Loss) Continuing Operations		 -23 -43 -52 -42 -64 -57 -69 -69 -31 -29 -50
Consolidated Net Income / (Loss)		 -23 -43 -52 -42 -64 -57 -69 -69 -31 -29 -50
Depreciation Expense		 0.53 1.38 1.28 1.14 2.30 2.88 2.64 2.70 2.78 2.86 3.17
Non-Cash Adjustments To Reconcile Net Income		 8.20 3.21 8.83 7.22 9.36 4.37 42 3.46 3.40 -0.48 0.83
Changes in Operating Assets and Liabilities, net		 -0.71 -1.59 0.37 1.48 2.68 -7.89 28 -4.01 54 2.77 -20
Net Cash From Investing Activities		 -1.44 -2.81 -0.15 -0.36 -0.65 -1.13 -0.48 -0.75 -1.45 -4.22 -1.20
Net Cash From Continuing Investing Activities		 -1.44 -2.81 -0.15 -0.36 -0.65 -1.13 -0.48 -0.75 -1.45 -1.47 -1.20
Purchase of Property, Plant & Equipment		 - - -0.15 -0.36 -0.65 -1.13 -0.55 -0.76 -1.52 -1.47 -1.20
Sale of Property, Plant & Equipment		 1.44 2.81 - - 0.00 0.00 0.07 0.01 0.07 0.00 0.00
Net Cash From Financing Activities		 1.80 0.40 32 99 56 18 155 -33 -2.52 73 -2.15
Net Cash From Continuing Financing Activities		 1.82 0.41 31 98 56 0.87 124 13 -1.12 73 0.00
Repayment of Debt		 - - 0.00 0.00 -1.42 -0.74 0.00 -1.79 -1.12 -1.64 0.00
Issuance of Debt		 1.82 0.41 0.36 0.30 2.27 0.71 1.29 0.00 0.00 0.00 0.00
Issuance of Common Equity		 0.00 0.00 31 96 54 0.00 123 15 0.00 74 0.00
Cash Interest Paid		 - - - - - - 2.55 - 0.87 - 0.61
Cash Interest Received		 0.49 0.26 - - - - 0.14 - 2.78 - 2.76

Quarterly Cash Flow Statements for ProQR Therapeutics

No quarterly cash flow statements for ProQR Therapeutics are available.

Annual Balance Sheets for ProQR Therapeutics

This table presents ProQR Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 69 128 126 132 121 237 183 153 174 132
Total Current Assets		 65 60 124 129 98 217 165 134 159 118
Cash & Equivalents		 62 58 121 126 93 212 101 132 155 108
Accounts Receivable		 2.55 2.48 - - - - - - 3.88 7.98
Current Deferred & Refundable Income Taxes		 - - - - - - - - 0.71 1.07
Plant, Property, & Equipment, net		 -0.95 3.01 2.13 2.74 23 20 0.00 0.00 15 15
Total Noncurrent Assets		 69 64 0.00 0.36 0.00 0.70 0.66 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 69 64 126 132 121 237 183 153 174 132
Total Liabilities		 13 17 20 27 52 109 112 107 82 74
Total Current Liabilities		 6.32 6.63 9.34 12 13 31 22 38 40 38
Short-Term Debt		 - - 0.00 - 2.41 9.92 4.03 0.34 5.23 5.99
Accounts Payable		 0.35 0.66 0.15 0.50 0.27 0.22 0.42 1.70 0.02 0.35
Current Deferred Revenue		 0.00 0.42 0.62 0.80 0.86 5.79 6.03 23 23 21
Other Taxes Payable		 -0.42 - 0.00 - 0.03 1.39 1.20 1.84 1.53 0.00
Other Current Liabilities		 6.39 5.56 8.55 10 9.01 14 11 11 11 11
Total Noncurrent Liabilities		 19 26 11 14 39 78 89 69 42 36
Capital Lease Obligations		 - - - - 19 17 15 15 11 11
Noncurrent Deferred Revenue		 - - - - 0.00 17 70 49 30 25
Total Equity & Noncontrolling Interests		 51 47 106 105 69 128 71 46 92 58
Total Preferred & Common Equity		 51 47 212 105 70 129 72 46 92 58
Preferred Stock		 - - 270 - 353 451 441 457 501 568
Total Common Equity		 51 47 -163 106 -283 -322 -370 -411 -409 -510
Common Stock		 0.99 1.75 1.98 2.42 2.64 3.39 3.61 3.73 4.46 5.06
Retained Earnings		 -80 -144 -178 -238 -315 -360 -406 -443 -442 -549
Other Equity Adjustments		 130 189 12 341 29 34 32 29 29 34

Quarterly Balance Sheets for ProQR Therapeutics

No quarterly balance sheets for ProQR Therapeutics are available.

Annual Metrics And Ratios for ProQR Therapeutics

This table displays calculated financial ratios and metrics derived from ProQR Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - 0.00 31,921,865.00 38,872,936.00 49,745,687.00 54,131,553.00 71,290,805.00 80,817,079.00 81,354,592.00 - 105,361,064.00
DEI Adjusted Shares Outstanding		 - 0.00 31,921,865.00 38,872,936.00 49,745,687.00 54,131,553.00 71,290,805.00 80,817,079.00 81,354,592.00 - 105,361,064.00
DEI Earnings Per Adjusted Shares Outstanding		 - 0.00 -1.64 -1.09 -1.27 -1.06 -0.95 -0.84 -0.77 - -0.95
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -68 -123 -34 -29 -45 -36 -45 -49 -25 -22 -36
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -51.52% -37.28% -20.38% -47.50%
Earnings before Interest and Taxes (EBIT)		 -93 -174 -52 -42 -64 -52 -65 -70 -32 -32 -50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -93 -172 -51 -41 -62 -49 -62 -67 -29 -29 -47
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -174 -28 23 -43 -58 -15 22 -26 -43 -49
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 51 45 -7.20 -9.09 13 -17 -88 -86 -66 -33
Increase / (Decrease) in Invested Capital		 0.00 51 -6.14 -52 -1.89 22 -30 -70 1.56 21 13
Book Value per Share		 $0.00 $1.99 $1.86 ($5.12) $2.72 ($5.69) ($5.95) ($5.18) ($5.09) ($5.03) ($4.85)
Tangible Book Value per Share		 $0.00 $1.99 $1.86 ($5.12) $2.72 ($5.69) ($5.95) ($5.18) ($5.09) ($5.03) ($4.85)
Total Capital		 0.00 58 56 117 119 110 199 95 66 108 75
Total Debt		 0.00 6.01 8.71 11 14 41 71 23 20 17 17
Total Long-Term Debt		 0.00 6.01 8.71 11 14 39 61 19 20 11 11
Net Debt		 0.00 -56 -50 -110 -112 -51 -141 -78 -111 -138 -91
Capital Expenditures (CapEx)		 -1.44 -2.81 0.15 0.36 0.65 1.13 0.48 0.75 1.45 1.47 1.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -3.77 -4.15 -6.15 -9.29 -5.06 -17 45 -35 -30 -23
Debt-free Net Working Capital (DFNWC)		 0.00 59 54 115 116 88 195 147 96 124 85
Net Working Capital (NWC)		 0.00 59 54 115 116 85 185 143 96 119 79
Net Nonoperating Expense (NNE)		 -45 50 18 13 19 21 23 20 6.01 6.66 14
Net Nonoperating Obligations (NNO)		 0.00 -0.39 -2.32 -113 -114 -57 -146 -159 -132 -157 -91
Total Depreciation and Amortization (D&A)		 0.53 1.38 1.28 1.14 2.30 2.88 2.64 2.70 2.78 2.86 3.17
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.99) $0.00 $0.00 ($1.28) ($1.38) ($0.93) ($0.96) ($0.91) ($0.35) ($0.33) ($0.47)
Adjusted Weighted Average Basic Shares Outstanding		 25.90M 0.00 0.00 38.87M 49.75M 54.13M 71.29M 71.64M 81.01M 105.21M 105.33M
Adjusted Diluted Earnings per Share		 ($0.99) $0.00 $0.00 ($1.28) ($1.38) ($0.93) ($0.96) ($0.91) ($0.35) ($0.33) ($0.47)
Adjusted Weighted Average Diluted Shares Outstanding		 25.90M 0.00 0.00 38.87M 49.75M 54.13M 71.29M 80.82M 81.35M 105.21M 105.33M
Adjusted Basic & Diluted Earnings per Share		 ($0.99) $0.00 $0.00 ($1.28) ($1.38) ($0.93) ($0.96) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 25.90M 0.00 0.00 40.24M 41.04M 50.06M 64.18M 80.82M 81.35M 86.09M 105.36M
Normalized Net Operating Profit after Tax (NOPAT)		 -68 -123 -34 -29 -45 -36 -45 -49 -25 -22 -36
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for ProQR Therapeutics

No quarterly metrics and ratios for ProQR Therapeutics are available.


Financials Breakdown Chart

ProQR Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ProQR Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

ProQR Therapeutics' net income appears to be on a downward trend, with a most recent value of -$49.51 million in 2025, rising from -$23.12 million in 2015. The previous period was -$28.74 million in 2024. View ProQR Therapeutics' forecast to see where analysts expect ProQR Therapeutics to go next.

ProQR Therapeutics' total operating income in 2025 was -$50.99 million, based on the following breakdown:
  • Total Gross Profit: $18.67 million
  • Total Operating Expenses: $70.17 million

Over the last 10 years, ProQR Therapeutics' total revenue changed from -$29.96 million in 2015 to $18.67 million in 2025, a change of -162.3%.

ProQR Therapeutics' total liabilities were at $74.39 million at the end of 2025, a 9.5% decrease from 2024, and a 468.2% increase since 2016.

In the past 9 years, ProQR Therapeutics' cash and equivalents has ranged from $57.82 million in 2017 to $212.24 million in 2021, and is currently $108.46 million as of their latest financial filing in 2025.

Over the last 10 years, ProQR Therapeutics' book value per share changed from 0.00 in 2015 to -4.85 in 2025, a change of -484.7%.


Related Companies

Financial statements for NASDAQ:PRQR last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
How much money does your next trade really require?
If a stock trades at $300, most investors assume they need $300 per share. Sean Allison says that assumption m...
Trade Thirsty | Sponsoredtc pixel
The only metrics you should watch as a day trader.
Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...
The TradingPub | Sponsoredtc pixel
60 years. Zero competitors.
One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...
Behind the Markets | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel